Literature DB >> 17720604

Analysis of oseltamivir active metabolite, oseltamivir carboxylate, in biological materials by HPLC-UV in a case of death following ingestion of Tamiflu.

Chiaki Fuke1, Yoko Ihama, Tetsuji Miyazaki.   

Abstract

An HPLC-UV method was established for determination of oseltamivir carboxylate, an active metabolite of oseltamivir, in biological materials. Oseltamivir carboxylate and floropipamide (internal standard) were extracted by using a mixed mode cation exchange extraction cartridge. The recovery yields of oseltamivir carboxylate from spiked blood at concentrations 0.1microg/ml and 1.0microg/ml were 103.8+/-16.9% and 95.0+/-4.3%, respectively. Linearity was obtained in the concentration from 0.1 to 3.0microg/ml. The detection limit was 0.04microg/ml (S/N=3). This method was applied to a case of death from falling after ingestion of a Tamiflu capsule containing 75mg of oseltamivir. Concentration of oseltamivir carboxylate in the femoral blood was 0.4microg/ml. The highest concentration in all specimens was in the liver at 18.3microg/g. In all brain samples, the concentrations were not higher than the quantification limit (0.1microg/g).

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17720604     DOI: 10.1016/j.legalmed.2007.07.003

Source DB:  PubMed          Journal:  Leg Med (Tokyo)        ISSN: 1344-6223            Impact factor:   1.376


  5 in total

Review 1.  Pharmacologic considerations for oseltamivir disposition: focus on the neonate and young infant.

Authors:  Susan M Abdel-Rahman; Jason G Newland; Gregory L Kearns
Journal:  Paediatr Drugs       Date:  2011-02-01       Impact factor: 3.022

2.  Simple and sensitive spectrofluorimetric method for the determination of oseltamivir phosphate in capsules through derivatization with fluorescamine.

Authors:  Zeynep Aydoğmuş
Journal:  J Fluoresc       Date:  2009-01-28       Impact factor: 2.217

3.  Low penetration of oseltamivir and its carboxylate into cerebrospinal fluid in healthy Japanese and Caucasian volunteers.

Authors:  S S Jhee; M Yen; L Ereshefsky; M Leibowitz; M Schulte; B Kaeser; L Boak; A Patel; G Hoffmann; E P Prinssen; C R Rayner
Journal:  Antimicrob Agents Chemother       Date:  2008-08-01       Impact factor: 5.191

4.  The inhibitory effect of kakkonto, Japanese traditional (kampo) medicine, on brain penetration of oseltamivir carboxylate in mice with reduced blood-brain barrier function.

Authors:  Kousuke Ohara; Shinji Oshima; Nanami Fukuda; Yumiko Ochiai; Ayumi Maruyama; Aki Kanamuro; Akio Negishi; Seiichi Honma; Shigeru Ohshima; Masayuki Akimoto; Shingo Takenaka; Daisuke Kobayashi
Journal:  Evid Based Complement Alternat Med       Date:  2015-02-19       Impact factor: 2.629

5.  Simultaneous quantification of prodrug oseltamivir and its metabolite oseltamivir carboxylate in human plasma by LC-MS/MS to support a bioequivalence study.

Authors:  Ajay Gupta; Swati Guttikar; Pranav S Shrivastav; Mallika Sanyal
Journal:  J Pharm Anal       Date:  2012-12-06
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.